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Abstract
The aims of this study were to generate chimeric human papillomavirus (HPV)-16 L1 virus-like particles (VLPs) in order to identify
immunogenic domains and conformational neutralizing epitopes, and to characterize the regions where a foreign epitope could be
introduced. We hypothesized that these regions could be on L1 protein loops since they are exposed on the surface of VLPs. The aims of
this study were achieved by mutating HPV-16 L1 proteins. Six amino acids encoding for the epitope 78–83 (DPASRE) of the hepatitis B
core (HBc) antigen were introduced within the different loops of the L1 protein at positions 56/57, 140/141, 179/180, 266/267, 283/284 or
352/353. All these chimeric L1 proteins were capable of self-assembly into VLPs. The antigenicity and immunogenicity of some of these
VLPs were reduced compared to the levels observed with wild-type VLPs. All were nevertheless able to induce neutralizing antibodies.
VLPs with insertion at position 266/267 induced lower levels of neutralizing antibodies, suggesting the involvement of residues situated on
FG loop in L1 neutralizing epitopes. All the chimeric L1 proteins except the one with insertion at position 56/57 were also able to induce
anti-HBc antibodies, thus suggesting exposure of the HBc epitope on the VLP surface. Taken together, our findings indicate the possibility
of designing HPV-derived vectors that are less immunogenic and suggest positions for insertion of defined immune epitopes or cell ligands
into L1 protein to be exposed on the surface of VLPs.
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
Over 100 human papillomaviruses (HPV) have been
identified to date (Stoler, 2000). They induce benign epi-
dermal and mucosal papillomas. In addition, the develop-
ment of cervical cancer, the second greatest cause of cancer
deaths in women worldwide (Ferlay et al., 1998), is strongly
associated with genital infection by specific types, such as
HPV-16, 18, 31, 33, 39, 45, 52, and 58 (Munoz, 2000;
Walboomers et al., 1999). Papillomaviruses are nonenvel-
oped viruses with an 8-kb double-stranded circular DNA for
the genome, encapsidated in a structure consisting of 72
capsomers composed of L1 and L2 proteins, the major and
minor capsid proteins, respectively (Baker et al., 1991; Trus
et al., 1997). The major capsid protein of HPV can self-
assemble into virus-like particles which have the size and
shape of virions (Kirnbauer et al., 1993; Le Cann et al.,
1994; Rose et al., 1993; Rossi et al., 2000).
Both linear and conformational epitopes have been iden-
tified on the surface of HPV L1 VLPs (Christensen et al.,
1996). It is now well established that conformational
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epitopes are responsible for neutralizing antibody produc-
tion (Christensen et al., 1994b; Giroglou et al., 2001; Rose
et al., 1994; White et al., 1998, 1999). The tertiary structure
of the L1 protein of HPV-16 is that of a jellyroll  sandwich
formed by the conserved sequences with additional hyper-
variable loops (Chen et al., 2000). The crystal structure of
HPV-16 L1 pentamers shows that the hypervariable loop
domains extending toward the outer surface of the capsid
(Chen et al., 2000). Mutagenesis of the hypervariable loop
domains has previously revealed the binding sites of several
neutralizing monoclonal antibodies generated against HPV-
11, including residues 120–140, 131–132, 246, and 346
(Ludmerer et al., 1996, 1997), or against HPV-6, including
residues 49–54 and 169–178 (McClements et al., 2001). In
addition, L1 residues 50, 266, and 282 of HPV-16 have been
implicated in the binding of neutralizing antibodies (Roden
et al., 1997; White et al., 1999). Slupetzky et al. (2001)
recently confirmed that regions around residues 282–286
and 351–355 contribute to BPV-1 L1 neutralizing epitopes.
The aims of this study were to generate chimeric
HPV-16 L1 VLPs (HPV cVLPs) in order to identify immu-
nogenic domains and conformational neutralizing epitopes.
We introduced a foreign sequence of six amino acids (aa)
encoding the epitope 78–83 (DPASRE) of the hepatitis B
core (HBc) antigen (Conway et al., 1998; Sallberg et al.,
1991) within the different hypervariable loops of the L1
protein. The chimeric L1 proteins generated were tested for
assembly into VLPs, for antigenicity and immunogenicity,
including their capacity to induce neutralizing antibodies,
and for their capacity to present the foreign epitope.
Results
Insertion of the HBc78–83 epitope into surface loops of
HPV-16 L1 protein does not interfere with capsid assembly
To obtain the chimeric HBc/HPV-16 L1 proteins, the
HBc epitope (DPASRE) was inserted between residues 56/
57, 140/141, 179/180, 266/267, 283/284, or 352/353 of the
L1 protein, corresponding to insertion in loops BC, DE, EF,
FG, and HI, respectively (Fig. 1). All chimeric proteins
were able to self-assemble into VLPs, which have a similar
shape to VLPs composed of wild-type (WT) L1 protein
(Fig. 2). Chimeric VLPs with insertion at positions 140/141,
179/180, 352/353, and 283/284 are the same size as wild-
type VLPs (50 nm). HPV-16 L1 mutant 56/57 produced
VLPs of 50 nm but also larger VLPs of 65 nm, and mutant
266/267 with insertion in the FG loop produced VLPs of 50
nm but also smaller VLPs of around 40 nm.
For the subsequent experiments, VLP preparations were
standardized according to their protein content, which is
consistent with their reactivity with CamVir-1 MAb when
denatured (data not shown).
Insertions into the FG loop of HPV-16 L1 protein
reduced VLP antigenicity
The antigenicity of chimeric VLPs was investigated us-
ing sera from mice immunized with wild-type HPV-16
VLPs. The reactivity of these sera against chimeric VLPs
with insertion at position 140/141 was similar to that ob-
served with wild-type HPV-16 VLPs (Table 1). In contrast,
reactivity was reduced when L1 was mutated at other posi-
tions. A dramatic decrease was observed when the
HBc78–83 epitope was inserted into the FG loop at posi-
tions 266/267 or 283/284 (Table 1).
The antigenicity of chimeric HPV-16 VLPs was also
analyzed using four anti-HPV-16 L1 Mabs, including Cam-
Vir-1 directed against a linear epitope (amino acids 204–
210) and H16.U4, H16.V5, and H16.E70 directed against
conformational epitopes. The reactivity of CamVir-1 and
H16.U4 MAbs toward chimeric and wild-type HPV-16
VLPs was similar (Table 1). Binding of H16.V5 and
H16.E70 MAbs to chimeric VLPs, with HBc epitope inser-
tion at position 56/57, 140/141, 179/180, or 352/353, was
identical to binding on wild-type HPV-16 VLPs. In contrast,
binding of these MAbs to the other two chimeric VLPs with
Fig. 1. Schematic representation of HBc/HPV-16 L1 chimeric proteins.
33J.-R. Sadeyen et al. / Virology 309 (2003) 32–40
insertion at position 266/267 or 283/284 (HPV-16 VLPs
mutated on FG loop) was considerably reduced.
Insertions into the FG loop of HPV-16 L1 protein
reduced the immunogenicity of the corresponding VLPs
The immunogenicity of chimeric VLPs was investigated
by testing the reactivity of the sera of four mice immunized
with wild-type or chimeric VLPs. Figure 3 shows that re-
activity to HPV-16 VLPs of sera from mice immunized with
L1 proteins with insertion at position 140/141 or 179/180
was similar to that observed with sera from mice immunized
with wild-type L1 VLPs. In contrast, sera from mice im-
munized with the other chimeric VLPs exhibited lower
reactivity. The reduction was more pronounced with sera
from mice immunized with VLPs composed of L1 proteins
with insertion of the HBc epitope at position 266/267 (Fig.
3) and was at a lower level for insertion at position 56/57,
283/284, or 352/353. Low reactivity of sera from mice
immunized with VLPs with HBc insertion at position 266/
267 was also observed when tested against autologous L1
226/267 VLPs. In addition, similar to the reactivity ob-
served with wild-type VLPs, a less pronounced reduction in
reactivity was observed with sera from mice immunized
with VLPs with insertion at positions 56/57, 283/284, and
352/353 when tested with each of the autologous VLPs,
respectively. Induction of HPV-16 neutralizing antibodies
was also estimated by testing the capacity of sera from
immunized mice to interfere with gene transfer by HPV-16
pseudovirions (Table 2). Neutralizing antibodies were de-
Fig. 2. Electron micrographs of HPV VLPs composed of wild-type HPV-16 L1 protein or chimeric HBc/HPV-16 L1 protein with insertion at position 56/57,
140/141, 179/180, 266/267, 283/284, or 352/353 are shown. VLPs were purified from nuclear extracts of Sf21 cells infected by recombinant baculovirus
encoding wild-type HPV-16 L1 or chimeric HBc/HPV-16 L1 proteins and then observed by transmission electron microscopy at a magnification of 1/50,000
(the bar represents 100 nm).
Table 1
Anti-VLP titers of monoclonal and polyclonal anti-L1 antibodies when tested against WT HPV-16 L1 VLPs and chimeric HBc/HPV-16 L1 VLPs
L1 VLPs Anti-VLP antibody titers
Monoclonal Polyclonal
Cam Vir-1 H16.U4 H16.V5 H16.E70 anti-VLPs
WT 3.2 103 7.1 104 7.8 106 1.4 105 1.2 104
L1 56/57 3.2 103 1.4 105 7.8 106 1.4 105 1.6 103
L1 140/141 3.2 103 1.4 105 7.8 106 7.1 104 2.5 104
L1 179/180 3.2 103 1.4 105 7.8 106 1.4 105 3.2 103
L1 266/267 1.3 104 1.4 105 1.0 102 4.0 102 4.0 102
L1 283/284 6.4 103 7.1 104 1.0 103 2.0 102 2.0 102
L1 352/353 1.3 104 2.8 105 7.8 106 1.4 105 3.2 103
Note. Titers were defined as the highest serial dilution which yielded an OD value greater than 0.200.
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tected in all mice immunized with wild-type HPV-16 VLPs
or chimeric VLPs and in none of those immunized with
HBc VLPs. A geometric mean titer of 2393 was observed
with wild-type VLPs, whereas it was only 237 in mice
immunized with mutant 266/267. A much lower reduction
in the geometric mean titer of neutralizing antibodies was
observed with other chimeric VLPs, with titers ranging from
673 to 1131.
The HBc78–83 epitope inserted in HPV-16 L1 loops is
exposed on the surface of the VLPs
To evaluate whether the inserted HBc sequence was
present on the surface of the particles, the chimeric HPV-16
L1 proteins were investigated for their capacity to induce
anti-HBc antibodies. Sera of four mice immunized with
HBc or chimeric HBc/HPV-16 L1 VLPs were analyzed by
ELISA using HBc VLPs. The results (Table 2) indicate that
all mice immunized with mutants corresponding to insertion
of the HBc epitope at positions 140/141, 179/180, 266/267,
283/284, and 352/353 developed anti-HBc antibodies, as
observed for mice immunized with HBc VLPs. In contrast,
none of the four mice immunized with VLPs composed of
L1 protein with the HBc78–83 epitope inserted at position
56/57 developed anti-HBc antibodies. Anti-HBc geometric
mean titers of 84, 100, 237, 100, and 79 were observed with
mutants 140/141, 179/180, 266/267, 283/284, and 352/353,
respectively. A geometric mean titer greater than 3200 was
observed in mice immunized with HBc VLPs.
Discussion
The aims of this study were to introduce a heterologous
sequence into the HPV-16 L1 protein to characterize the
conformational neutralizing epitopes of HPV-16 L1 VLPs,
and the regions where a foreign epitope could be introduced
at the surface of the VLPs. X-ray crystallographic analysis
of HPV-16 L1 pentamers have identified loops at the sur-
face of the structure (Chen et al., 2000). Because mutations
Fig. 3. The immunogenicity of chimeric VLPs: detection of anti-HPV-16 VLP antibodies in serum of mice immunized with WT and chimeric VLPs is shown.
Anti-VLP antibodies were obtained by subcutaneous immunization of four mice with purified WT or chimeric VLPs at days 0, 6, 14, and 28. Blood samples
were collected 11 days after the last injection and anti-VLP reactivity was investigated by ELISA using WT VLPs as antigen. OD values reported are the
mean of the OD values observed in each of the four mice.
Table 2
Immunogenicity of chimeric HBc/HPV-16 L1 VLPs: number of mice
with neutralizing antibodies against HPV VLPs (1/50) and antibodies
against HBc VLPs (1/100)
VLPs HPV-neutralizing
antibodies
Anti-HBc
Positive/tested GMTa Positive/tested GMTa
L1 WT 4/4 2393 0/4 50
L1 56/57 4/4 673 0/4 50
L1 140/141 4/4 673 2/4 84
L1 179/180 4/4 800 2/4 100
L1 266/267 4/4 237 4/4 237
L1 283/284 4/4 1131 2/4 100
L1 352/353 3/3 800 3/3 79
HBc 0/4 50 4/4 3200
Note. HPV neutralizing antibody titers were defined as the highest serial
dilution which yielded more than 80% neutralization of the luciferase
expression obtained using HPV-16 pseudovirions. Anti-HBc ELISA titers
were defined as the highest serial dilution which yielded an OD value
greater than 0.150.
a GMT, geometric mean titers.
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into loops have lower chances of affecting the tridimen-
sional protein structure compared to mutations into  heli-
ces or  sheets, L1 loops appeared to be the most promising
positions for insertion of an exogenous sequence into the L1
protein. The study focused on loops BC, DE, EF, FG, and
HI, where residues involved in L1 B cell epitopes have been
identified (Christensen et al., 1996; Ludmerer et al., 1996;
McClements et al., 2001; Roden et al., 1997; White et al.,
1999). An exogenous sequence, DPASRE, corresponding to
the HBc epitope 78–83 was introduced at position 56/57,
140/141, 179/180, 266/267, 283/284, or 352/353 of the L1
protein. We evaluated the ability of the above L1 mutant
proteins to form particles. All the chimeric L1 proteins
produced self-assembled into VLPs of similar appearance to
VLPs composed of wild-type L1 protein. However, larger
VLPs were observed for the mutant with insertion in the BC
loop and smaller VLPs for the two mutants with insertion in
the FG loop. Thus, insertion of six amino acids into loops
does not affect assembly of the HPV-16 L1 protein at the
positions investigated, although other mutations within
loops destabilize the structure (Kirnbauer et al., 1993; un-
published data).
Using murine immune sera obtained with wild-type
HPV-16 L1 VLPs, the antigenicity of the chimeric VLPs
composed of L1 proteins containing the HBc78-83 epitope
at position 52/53, 140/141, 179/180, or 352/353 appeared
similar to that of wild-type VLPs. In contrast, the antige-
nicity of the L1 mutant containing the HBc sequence at
position 266/267 or 283/284 was reduced and suggested that
L1 immunodominant epitopes are located within the FG
loop. To determine whether epitopes recognized by anti-L1
MAbs (H16.V5, H16.E70, and H16.U4) were affected by
insertion of a foreign sequence, we tested the reactivity of
these antibodies to chimeric VLPs. The reactivity of
H16.U4 MAb was similar with wild-type and mutant VLPs.
In contrast, the reactivity of the other two monoclonal an-
tibodies (H16.V5 and H16.E70) to HBc/HPV-16 VLPs was
dramatically reduced when insertion into L1 protein was
performed at position 266/267 or 283/284. These findings
confirmed that H16.V5 and H16.E70 have overlapping
binding sites, which are distinct from the H16.U4 epitope
(White et al., 1999). Our findings also suggest that the
H16.V5 and H16.E70 binding sites involve FG loop amino
acids. They confirmed results recently published by Slu-
petzky et al. (2001) indicating that insertion between resi-
dues 286/287 and 281/287 affects H16.V5 and H16.E70
epitopes and by Christensen et al. (2001) indicating that
H16.V5 antibody is able to bind hybrid VLPs H11:16-
(266–297). Our findings are also in agreement with the
observation that the H16.E70 epitope is lost or restored by
substitutions at positions 266 and/or 282 (Roden et al.,
1997; White et al., 1999). Residue 50 of the HPV-16 L1
protein has previously been shown to be important for
H16.V5 and H16.E70 epitopes (White et al., 1999), sug-
gesting that, in addition to the FG loop, the BC loop is part
of the antibody binding site. Since our insertion at position
56/57 had no effect on the H16.V5 and H16.E70 epitopes,
our findings could indicate that the BC loop is not involved
in these epitopes and suggest that mutation at position 50
acts at a distance by distorting the VLP conformation, as
also proposed by Christensen et al. (2001). This is in agree-
ment with the fact that we observed that the F to L mutation
at position 50 of the HPV-16 L1 gene of the Phil strain
(Touze´ et al., 1998), a strain identical to the 114K strain,
abolished the capacity of the L1 protein to self-assemble
into VLPs (unpublished data).
When injected into animals HPV VLPs induce high
levels of antibodies directed at both linear (Christensen et
al., 1996; Ludmerer et al., 1997) and conformational (Chris-
tensen et al., 1996; Ludmerer et al., 1996, 1997) epitopes.
Evidence suggests that antibodies, such as H16.V5,
H16.E70, and H16.U4 MAb, that are generated by confor-
mational epitopes are neutralizing (Christensen et al.,
1994a, 1994b; Giroglou et al., 2001; Roden et al., 1996,
1997; Rose et al., 1994; White et al., 1998, 1999). The
epitope recognized by H16.V5 MAb has been suggested to
be immunodominant since H16.V5 MAb is able almost
completely to block HPV-16 VLP recognition of 75% of
human HPV-16-positive sera (Wang et al., 1997). In order
to investigate whether VLPs with reduced H16.V5 reactiv-
ity have a reduced capacity to induce neutralizing antibod-
ies, mice were immunized with the different chimeric HBc/
VLPs. The results indicate that the immunogenicity of the
chimeric VLPs composed of L1 protein with a heterologous
sequence inserted in loops BC, FG, or HI (position 56/57,
266/267, 283/284, or 352/353) were slightly less immuno-
genic than VLPs composed of wild-type L1 protein, mutant
266/267 being the least immunogenic capsid. However,
immunization with chimeric VLPs induced neutralizing an-
tibodies, with mutant 266/267 inducing the lowest neutral-
izing activity. This suggests that the FG loop is involved in
the production of neutralizing antibodies. Interestingly,
VLP mutants with the HBc epitope at position 283/284, but
deficient in H16.V5 and H16.E70 epitopes, induced neutral-
izing antibodies at only half the level observed with wild-
type VLPs, suggesting that the H16.V5 epitope is not the
immunodominant neutralizing epitope but could be close to
the immunodominant epitope. The H16.V5 MAb might
therefore block HPV-16 VLP recognition of human HPV-
16-positive sera by steric inherence. This also suggests the
presence of other neutralizing epitopes within the L1 major
capsid protein that could become immunodominant when
H16.V5 and H16.E70 epitopes are lost, as in the situation
described for epitopes on the HIV1 gp41 protein (Cleveland
et al., 2000).
Our findings also contribute to the identification of po-
sitions within the L1 structure where foreign sequences can
be introduced and expressed on the surface of VLPs. When
inserted into loops DE, EF, FG, and HI (position 140/141,
179/180, 266/267, 283/284, or 352/353), the HBc epitope
induced production of specific antibodies. These findings
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confirm those obtained by Christensen et al. (2001), who
generated antibodies against HPV-16 sequences introduced
into FG and HI loops of HPV11. This is also in agreement
with the results of Chackerian et al. (1999) and Slupetzky et
al. (2001), who reported that an immune response against a
heterologous sequence could be obtained by insertion into
the DE and HI loops of BPV-1, respectively. We found that
insertion into the FG loop of HPV-16 at position 266/267 is
the most effective for the induction of anti-HBc antibodies,
suggesting the presence of the heterologous sequence on the
VLP surface and in correlation with the fact that the HPV-
immunodominant epitope is situated on this loop. However,
the HBc reactivity could be explained by degradation or
misfolding of the VLPs. The different chimeric VLP prep-
arations were of similar appearance, mainly well-formed
VLPs, when observed by electronmicroscopy, and the fact
that no anti-HBc immune response was induced by L1-HBc
56/57 L1 VLPs suggests that the anti-HBc reactivity of the
other chimeric VLPs was due to the presence of the HBc
epitope on the surface of the VLPs rather than to their
partial degradation or misfolding.
In conclusion, our findings indicate that chimeric L1
proteins obtained by insertion of a foreign sequence within
the different loops retain VLP assembly properties. Our
results also support the role of the FG surface loop as an
HPV-16 neutralizing determinant and suggest that insertion
of a foreign sequence into this loop disrupts the H16.V5
epitope and the overlapping H16.E70 epitope, but only
reduces (and does not abolish) the capacity of chimeric
VLPs to induce neutralizing antibodies. Our findings also
define the regions where a foreign epitope could be intro-
duced and exposed on the surface of VLPs and therefore
provide a rational approach to designing better prophylactic
HPV vaccines that can provide protection against multiple
HPV types by inserting L1 or L2 epitopes in order to
generate higher levels of cross-protection.
Materials and methods
Generation of HPV-16 L1 mutants
DNA-encoding chimeric L1 proteins were obtained by
mutagenesis using a two-step PCR protocol. In the first step,
one fragment was generated using the wild-type L1 DNA
sequence as template and HPV5L1 16 and INS3 56/57,
INS3 140/141, INS3 179/180, INS3 266/267, INS3 283/
284, and INS3 352/353 (Table 3) as primers for mutants L1
56/57, 140/141, 179/180, 266/267, 283/284, and 352/353,
respectively. Another fragment was amplified using the
wild-type L1 DNA sequence as template and HPV3L1 16
and INS5 56/57, INS5 140/141, INS5 179/180, INS5
266/267, INS5 283/284, and INS5 352/353 (Table 3) as
primers for mutants L1 56/57, 140/141, 179/180, 266/267,
283/284, and 352/353, respectively. The two fragments gen-
erated for each mutant contained the HBc78–83 encoding
sequences in 3 and 5 and a BglII restriction site in 5 and
3, respectively. These fragments overlapped over their 3
and 5 sequences and were used in the second PCR step as
DNA templates using HPV5L1 16 and HPV3L1 16 prim-
ers. The resulting DNA sequences had an HBc78–83-en-
coding sequence between L1 bases 168/169, 420/421, 537/
538, 798/799, 849/850, and 1056/1057 and in 3 and 5
BglII restriction sites for the mutants L1 56/57, 140/141,
179/180, 266/267, 283/284, and 352/353, respectively. The
wild-type L1 gene was amplified using DNA extracted from
a cervical cancer patient from the Philippines (Touze´ et al.,
1998) as template and HPV5 L1 16 and HPV3 L1 16 as
primers. These fragments contained a BglII restriction site
in 3 and 5.
The HPV-16 L1 gene and chimeric HBc78–83/HPV-16
L1 genes were then cloned into the PCRII-TOPO vector
(Invitrogen, Cergy Pontoise, France) after addition of A at
PCR fragment extremities using Taq polymerase (Invitro-
gen) and were then sequenced with an ABI PRISM 377
Table 3
Sequence of oligonucleotides used for construction of HBc78-83/HPV16 L1 genes
Name Sequence
INS5 56/57 ACGACCCAGCGTCCCGGGAAAATAACAAAATATTAGTTCC
INS5 56/57 TTTTCCCGGGACGCTGGGTCGTTAGGTTTTTTAATAGGAA
INS5 140/141 GTGACCCAGCGTCCCGGGAAGTGGATAATAGAGAATGTAT
INS3 140/141 ACTTCCCGGGACGCTGGGTCACCTGCATTTGCTGCATAAT
INS5 179/180 CAGACCCAGCGTCCCGGGAAGTAAATCCAGGTGATTGTCC
INS3 179/180 ACTTCCCGGGACGCTGGGTCTGCAACATTGGTACATGGGG
INS5 266/267 CTGACCCAGCGTCCCGGGAAGTTGGTGAAAATGTACCAGA
INS3 266/267 ACTTCCCGGGACGCTGGGTCAGCACCAGCCCTATTAAATA
INS5 283/284 CTGACCCAGCGTCCCGGGAAGCAAATTTAGCCAGTTCAAA
INS3 283/284 GCTTCCCGGGACGCTGGGTCAGTAGACCCAGAGCCTTTAA
INS5 352/353 AAGACCCAGCGTCCCGGGAAACTACATATAAAAATACTAA
INS34 352/353 GTTTCCCGGGACGCTGGGTCTTCTGAAGTAGATATGGCAG
HPV5 L1 16 CCAGATCTATGTCTCTTTGGCTGCCTAGTGAGGC
HPV3 L1 16 CCAGATCTTTACAGCTTACGTTTTTTGCGTTTAG
Note. Bold and underlined sequences correspond to the HBc78-83 encoding sequence. Bold sequences are BglII restriction sites.
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automated sequencing system (Perkin–Elmer/Applied Bio-
systems, Courtaboeuf, France).
Generation of VLPs
HPV-16 L1 gene and chimeric HBc78–83/HPV-16 L1
genes obtained from the pCRII-TOPO vector by digestion
with the BglII restriction enzyme were subcloned into the
pFastBacDual plasmid (Invitrogen) linearized with a
BamHI restriction enzyme. Recombinant baculoviruses en-
coding HPV-16 L1 protein and chimeric HBc78–83—
HPV-16 L1 proteins were generated using the Bac-to-Bac
baculovirus expression system according to the manufac-
turer’s instructions (Invitrogen).
Sf21 cells, maintained in Grace’s insect medium supple-
mented with 10% fetal calf serum (FCS, Invitrogen), were
infected with the different recombinant baculoviruses and
incubated for 72 h at 27°C. Cells were harvested (500 g for
10 min), resuspended in phosphate-buffered saline (PBS)
containing Nonidet P-40 (0.5%), pepstatin (10 g/ml,
Sigma Aldrich, Saint Quentin Fallavier, France), and leu-
peptin (1 g/ml, Sigma Aldrich), and allowed to stand for
30 min at 4°C. Cell lysates were then centrifuged at 14,000
g for 15 min at 4°C. Pellets were resuspended in PBS
containing pepstatin (10 g/ml) and leupeptin (1 g/ml)
and sonicated by three 15-s burst at 60% maximal power
(Vibra Cell; Bioblock Scientific, Strasbourg, France). Frac-
tions were then loaded on the top of a preformed CsCl
gradient and centrifuged at equilibrium in a Beckman SW28
rotor (22 h, 27,000 rpm, 4°C). Gradient fractions were
analyzed for density by refractometry using an Abbe´ refrac-
tometer (Bioblock Scientific) and were tested for the pres-
ence of wild-type or chimeric L1 protein by electrophoresis
in a 10% sodium dodecyl sulfate–polyacrylamide gel (SDS–
PAGE) followed by Coomassie blue staining. CsCl frac-
tions containing L1 protein were pooled, diluted in PBS,
and pelleted in a Beckman SW 28 rotor (3 h, 28,000 rpm,
4°C). After centrifugation, VLPs were resuspended in 0.15
M NaCl and sonicated by one 5-s burst at 60% maximal
power. Protein content was determined using the Mi-
croBCA kit (Pierce, Touzard et Matignon, France) and
assembly into VLPs verified by electron microscopy. For
this purpose, purified VLP preparations were applied to
carbon-coated grids, negatively stained with 1.5% uranyl
acetate, and observed at 50,000 nominal magnification
using a JEOL 1010 electron microscope.
For generation and detection of anti-HBc antibodies,
HBc VLPs were generated according to a previously de-
scribed procedure (Touze´ and Coursaget, 1998) with the
exception that the full-length HBc gene was cloned and
expressed.
Antibodies
Anti-HPV-16 L1 MAbs H16.V5, H16.E70, and H16.U4
were the kind gifts of N.D. Christensen (The Milton S.
Hershey Medical Center, Hershey, PA, USA). CamVir-1
MAb directed against L1 epitope 204–210 (McLean et al.,
1990) was obtained from Pharmingen (Newcastle, UK).
Anti-L1 VLP antisera were also obtained by subcutane-
ous immunization of four mice with each of the VLP prep-
arations. Six- to 8-week-old female C57BL/6 mice (IFFA
Credo, St. Germain l’Arbresle, France) received 5 g of
purified VLPs composed of wild-type or chimeric L1 pro-
tein in 0.15 M NaCl and 0.2% AlOH3 as adjuvant. The
immunization schedule consisted of one injection at days 0,
6, 14, and 28. Blood samples were obtained 11 days after
the last injection. For the group immunized with mutant
352/353, one mouse died during the experiment and thus
results were recorded in three animals.
Anti-HBc antiserum was obtained as previously de-
scribed for anti-L1 VLP antiserum except that immuniza-
tion was performed with purified HBc VLPs.
As for neutralizing antibodies against HPV-16, the serum
samples were tested for antibodies against both anti-L1 and
anti-HBc antibodies.
Detection of anti-L1 and anti-HBc antibodies by ELISA
Two hundred nanograms of VLPs, native or dissociated
by treatment with 0.3 M Na2CO3, pH 10.6, and 0.01 M
dithiotreitol (DTT) in PBS for 15 min at 37°C, was distrib-
uted in a 96-well plate (Nunc Maxisorp, Merck Eurolab,
Strasbourg, France) and incubated at 4°C overnight. After
two washing with PBS–Tween (0.1%), the wells were sat-
urated with PBS supplemented with 1% FCS for 1 h at
37°C. Anti-L1 or anti-HBc antibodies diluted in PBS–
Tween (0.1%)–FCS (1%) were then added to the wells and
incubated for 1 h at 37°C. After four washes, peroxidase-
conjugated goat antimouse Ig Fc (Sigma Aldrich) diluted
1:1000 in PBS–Tween (0.1%)–FCS (1%) was added to the
plates and incubated for 1 h at 37°C. After four washes, 0.4
mg/ml of o-phenylenediamine and 0.03% hydrogen perox-
ide in 25 mM (CH2COOH)2 and 50 mM Na2HPO4 were
added. After 30 min, the reaction was stopped with 4 N
H2SO4 and absorbance was read at 490 nm. For data anal-
ysis, optical density (OD) values obtained in the absence of
the first antibodies were subtracted from OD values of test
samples.
All experiments were performed twice independently
and yielded similar results.
Detection of neutralizing antibodies
Neutralization of the pseudovirions with anti-VLP anti-
bodies was investigated by inhibition of gene transfer ac-
cording to a previously described protocol (Bousarghin et
al., 2002). Briefly, 10,000 SV40-transformed COS-7 kidney
cells, cultured in complete Dulbecco’s modified Eagle’s
medium (Invitrogen, DMEM supplemented with 10% FCS,
100 IU/ml of penicillin, and 100 g/ml of streptomycin)
were seeded in 96-well plates. After 1 day at 37°C, cells
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were washed twice with incomplete DMEM medium and
resuspended by pipetting into 50 l of incomplete DMEM
medium. VLPs was mixed with pCMV Luc plasmid (Clon-
tech, Ozyme, Montigny le Bretonneux, France) linearized
by EcoRI digestion in 20 l of 33 mM NaCl, pH 5, in a 10:1
weight ratio. After 30 min incubation at room temperature
the pseudovirions obtained were then added to each test
well. After 3 h at 37°C, 150 l of complete DMEM was
added to cells. Luciferase gene expression was measured by
luminescence assay (Luciferase reporter gene assay with
constant light signal, Roche Molecular Biochemical, Mey-
lan, France). The luminescence was integrated over 10 s
(Victor2, Wallac, Perkin–Elmer, France) and results were
expressed as counts per second (cps) per well. The quantity
of DNA/VLP complexes was adjusted to give a luciferase
activity of around 1500 cps corresponding to 10 ng of DNA
per well. Thirty microliters of anti-VLP antibodies diluted
from 1/50 to 1/6400 in incomplete DMEM medium was
added to pseudovirions and incubated at 37°C for 30 min
before addition to the cells. Cells were then incubated for
48 h at 37°C and luciferase gene expression was measured
by luminescence assay. Neutralizing antibodies were con-
sidered to be present for inhibition greater than 80%. The
experiments were performed in duplicate. Results were ex-
pressed as the mean geometric titers obtained for the four
mice immunized with the same chimeric VLPs.
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